WinstonWınston
Back
Terumo Corporation logo

Terumo Corporation

TRUMY
67
Medical - Instruments & Supplies · Healthcare
Exchange
Other OTC
Winston Score
67
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Good
Growth
Strong
Cash Flow
Exceptional
Stability
Exceptional
Valuation
Good
Dividends
Weak

Winston Score History

The full picture

Terumo Corporation is a Japanese medical device company that makes equipment used inside hospitals and clinics. Its main products include blood bags, syringes, catheters, and devices used in heart surgeries and blood vessel procedures. Terumo sells to hospitals, blood banks, and healthcare systems around the world, and it is one of Japan's largest medical device makers.

Terumo earns money by selling its medical products directly to healthcare providers and through long-term supply relationships with hospitals. The company operates globally, with significant revenue coming from Japan, the United States, Europe, and Asia. Its moat comes from strong regulatory approvals, trusted brand relationships with hospitals, and specialized manufacturing know-how that takes years to replicate. The key growth driver is expanding its cardiovascular and interventional device business, particularly in the U.S. and emerging markets, though currency fluctuations and pricing pressure from hospital procurement systems remain ongoing risks.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+15.9% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+41.2% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

2.0%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$348.6B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Terumo Corporation is a rare growth stock that's already generating positive cash flow while growing at 16%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
57.3%
Premium pricing power — 57.3% gross margin
Profit after running costs
Operating Margin
22.1%
Excellent — 22.1% operating margin
Return on the money invested
ROCE
9.9%
Below par — 9.9% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+16.0%
Fast-growing sales (+16.0% YoY)
Profit growth
EPS YoY
+31.6%
Earnings growing fast (+31.6% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
167%
Turns 167% of profit into real cash
Spare cash per sale
FCF Margin
16.2%
Converts sales into free cash efficiently (16.2%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.23
Conservative — low debt load (0.23)
Covers its interest
Interest Cover
57.44x
Comfortably covers interest (57.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
23.5x
no trend
Growth-priced — P/E 23.5

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+5.6
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (23.5 → 17.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
1.02%
no trend
Small dividend — 1.02% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
-38.1%
no trend
Dividend cut (-38.1% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial